Today, SCIENION and its subsidiary Cellenion, both companies part of the bioconvergence powerhouse BICO, announced the release of the proteoCHIP LF 48. This chip represents the first commercially available solution enabling reproducible automated miniaturized single-cell proteomics sample preparation and standardized workflow for label-free single-cell mass spectrometry-based proteomics analysis. The proteoCHIP LF 48 was developed in […]
Read MoreTogether with numerous guests from politics, economics, life sciences and medical diagnostics, SCIENION the precision liquid handling specialist and part of bioconvergence powerhouse BICO, today celebrated the opening of new state of the art facilities in Portsmouth. More than 1,000 square meters will enable SCIENION UK to run customer R&D projects including single cell applications. […]
Read MoreHighfield Diagnostics Ltd (HDx) and SCIENION GmbH have signed a Memorandum of Understanding (MoU) regarding the development and deployment of equipment which can mass manufacture lateral flow tests (LFTs) that incorporate HDx’s flowDx technology. The MoU lays out the framework of the cooperation, which will include utilization of SCIENION’s world-class design and manufacturing capabilities to […]
Read MoreSCIENION GmbH, a BICO company and the precision liquid handling technology company powering life sciences and diagnostics for the future of health, today appointed Dr. Frauke Hein as co-Chief Executive Officer (CEO) alongside current CEO Dr. Holger Eickhoff, effective immediately. Hein and Eickhoff will lead the firm as co-CEOs during a transition period, after which […]
Read MoreDie SCIENION GmbH, ein BICO-Unternehmen und Anbieter von Präzisions-Flüssigkeitstechnologien, die Life Sciences und Diagnostik für die Zukunft der Gesundheit voranbringen, hat heute Dr. Frauke Hein mit sofortiger Wirkung zum Co-Chief Executive Officer (CEO) neben dem derzeitigen CEO Dr. Holger Eickhoff ernannt. Hein und Eickhoff werden das Unternehmen während einer Übergangsphase als Co-Geschäftsführer leiten. Danach wird […]
Read MoreTogether with numerous guests from politics, economics and science, SCIENION GmbH today celebrated the laying of the foundation stone of its new headquarters in Berlin Adlershof. The building complex will be constructed on a space of over 3000m², enabling the company to bundle global activities from a site with sufficient space to pave the way […]
Read MoreDie SCIENION GmbH hat heute mit zahlreichen Gästen aus Politik, Wirtschaft und Wissenschaft die Grundsteinlegung zum Neubau ihrer neuen Unternehmenszentrale in Berlin Adlershof gefeiert. Hier entsteht nun auf einer Fläche von rund 3000 m² ein viergeschossiges Gebäude, das die Bündelung der globalen Aktivitäten künftig von einem ausreichend großen Standort ermöglicht und die weitere Expansion des […]
Read MoreGILUPI GmbH and SCIENION AG today announced that the companies intend to intensify their collaboration in the field of single circulating tumor cell (CTC) analysis. CTCs are rare cells that can be found in the peripheral blood of cancer patients, often causing metastasis. Their potential in the diagnosis and treatment of cancer has initiated worldwide […]
Read More
SCIENION AG, located in the Technology Park Adlershof since its foundation in 2001, today announced that the expanding company will build larger new headquarters at Wagner-Régeny Street in the same district of Berlin. In February 2020, SCIENION acquired the leasehold for the 3,037 m² state-owned property from urban development agent WISTA.Plan GmbH. The building permit […]
Read More
Die SCIENION AG, die bereits seit Firmengründung 2001 im Technologiepark Adlershof ansässig ist, vergrößert sich weiter und baut ihren neuen Hauptsitz an der Wagner-Régeny-Straße in Berlin Adlershof. Für das 3.037 m² große landeseigene Grundstück hat das Life-Science-Unternehmen im Februar 2020 vom städtebaulichen Entwicklungsträger WISTA.Plan GmbH das Erbbaurecht erworben. Auch die Baugenehmigung liegt vor und so […]
Read More